- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02923011
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
July 13, 2023 updated by: Matthew Bucknor
Phase III Study to Compare the Effectiveness of Magnetic Resonance Guided Focused Ultrasound With Computed Tomography Guided Radiofrequency Ablation for Treatment of Osteoid Osteomas
Osteoid osteomas are painful, benign bone tumors that occur most frequently in young males between ages 10 and 20 years.
The goal of the proposed study is based on the premise that MRgFUS is noninferior to CT-guided radiofrequency ablation (CTgRFA), in terms of pain reduction following treatment of osteoid osteomas, and offers possible improvements with regards to 1) post-procedural pain, 2) clinical resource utilization, 3) patient experience, and/or 4) adverse events.
The data from the current study would provide clinicians important information in deciding between treatment options for ablation of osteoid osteomas.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
56
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maya Aslam
- Email: maya.aslam@ucsf.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Recruiting
- Stanford Medical Center
-
Contact:
- Krithika Rupnarayan
- Email: krupnara@stanford.edu
-
Principal Investigator:
- Pejman Ghanouni, MD, PhD
-
San Francisco, California, United States, 94107
- Recruiting
- UCSF Imaging Center
-
Contact:
- Maya Aslam
- Email: maya.aslam@ucsf.edu
-
Principal Investigator:
- Matthew Bucknor, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Men and women ages ≥ 8 years old.
- Diagnosis of osteoid osteoma as confirmed when a musculoskeletal radiologist and orthopedic oncologist agree that a patient's imaging and clinical history are most compatible with the diagnosis of osteoid osteoma. A patient referred by a clinician other than orthopedic oncologist will require a clinic visit with an orthopedic oncologist for study inclusion.
- Patients must have medically uncontrolled pain from an osteoid osteoma, as defined by pain, which, in the view of the referring orthopedic oncologist significantly interferes with that patient's activities of daily living. Pain may be refractory to management with medications because of inadequate pain control, or because of side effects of the pain medication.
- If patients have an additional site of pain, it must be 2 points less severe and distinguishable from the pain at the osteoid osteoma site.
- Patients (or guardians/parents) who are able and willing to give consent (or assent where applicable) and able to attend all study visits.
- No prior interventional therapy for the osteoid osteoma.
- Able to safely undergo MRI exam, tolerate being in an MRI scanner, and receive anesthesia/sedation for the treatment.
- Targeted bone/tumor interface is accessible to the ExAblate device and located in a rib, extremity (excluding intra-articular location), pelvis, shoulders (including clavicles), or the sternum.
- Targeted lesion must be deeper than 1 cm from the skin.
- Targeted lesion must be clearly visible by non-contrast MRI.
- Karnofsky Performance Status > 60.
Exclusion Criteria:
- Patients a) who need surgical stabilization of the affected bone (elevated fracture risk) or b) whose targeted tumor is at an impending fracture site, as determined by the referring orthopedic oncologist.
- Targeted tumor in the skull/spine.
- Targeted tumor is < 1 cm from a major nerve.
- Pregnancy.
- Patients with an acute medical condition (e.g. pneumonia, sepsis) that is expected to hinder them from completing this study.
- Patients with unstable cardiac status including: patients on anti-arrhythmic drugs, unstable angina pectoris, documented myocardial infarction within six months of protocol entry, congestive heart failure requiring medication (other than diuretic).
- Severe hypertension (diastolic BP > 100 on medication)
- Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices.
- Patients with an active infection or severe hematological, neurological, or other uncontrolled disease.
- Severe cerebrovascular disease.
- Known intolerance or allergy to medications used for sedation/anesthesia.
- Known intolerance or allergy to MR contrast agent (gadolinium chelates).
- Patients unable to communicate with the investigator and staff.
- Patients with persistent pain undistinguishable from the target lesion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: MRgFUS
Magnetic resonance-guided focused ultrasound ablation
|
Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma
|
Active Comparator: CTgRFA
Computed tomography-guided radiofrequency ablation
|
Computed tomography-guided radiofrequency ablation of osteoid osteoma
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of resolution of pain (worst visual analog scale score over last 24 hours < 2.0)
Time Frame: 1 month
|
1 month after treatment, worst VAS score over the last 24 hours will be assessed
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure time
Time Frame: Treatment day
|
On the day of the treatment, the procedure time will be recorded
|
Treatment day
|
Patient preference
Time Frame: 2 weeks
|
2 weeks after treatment, patient preference surveys will be assessed
|
2 weeks
|
Patient quality of life
Time Frame: 1 month
|
1 month after treatment, patient quality of life surveys will be assessed
|
1 month
|
Medication use
Time Frame: 5 days before, five days after, 1 month after
|
Self reported medication use for 5 days before, five days after, and 1 month after the treatment
|
5 days before, five days after, 1 month after
|
Adverse events
Time Frame: 1 month
|
All adverse events occurring within the first month will be recorded at 1 month following the procedure
|
1 month
|
Worst VAS
Time Frame: First 5 days, 1 week, 2 weeks, 3 weeks, 1 month, 6 months, 12 months
|
Worst VAS over the last 24 hours will be assessed for each of the first 5 days following the treatment and then at 1 week, 2 weeks, 3 weeks, 1 month, 6 months, and 12 months following the treatment
|
First 5 days, 1 week, 2 weeks, 3 weeks, 1 month, 6 months, 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthew Bucknor, MD, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2017
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
September 30, 2016
First Submitted That Met QC Criteria
October 3, 2016
First Posted (Estimated)
October 4, 2016
Study Record Updates
Last Update Posted (Actual)
July 17, 2023
Last Update Submitted That Met QC Criteria
July 13, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FUS513
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoid Osteoma
-
Children's National Research InstituteCompletedOsteoid OsteomaUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedOsteoid OsteomaFrance
-
University of Roma La SapienzaUnknown
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Children's National Research InstituteActive, not recruiting
-
University Hospital, Strasbourg, FranceRecruitingPainful Bone Metastases | Superficial Osteoid OsteomaFrance
-
The Hospital for Sick ChildrenSunnybrook Health Sciences CentreCompletedPain | Osteoid Osteoma | Benign Bone TumorCanada
-
Federico II UniversityCompleted
-
Shenzhen Geno-Immune Medical InstituteRecruitingSarcoma | Ewing Sarcoma | Osteoid SarcomaChina
-
Shenzhen Geno-Immune Medical InstituteThe Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children...Recruiting
Clinical Trials on MRgFUS
-
InSightecCompletedParkinson's DiseaseUnited States
-
InSightecCompleted
-
Istituto Ortopedico RizzoliCompletedOsteoarthritis | Hand Osteoarthritis | Hip OsteoarthritisItaly
-
University of Roma La SapienzaUnknownPrimary Pain Palliation in Bone Metastases Treated With Magnetic Resonance-guided Focused UltrasoundSecondary Malignant Neoplasm of BoneItaly
-
Istituto Ortopedico RizzoliCompletedOsteoarthritis | Osteoarthritis, Knee | Osteo Arthritis KneeItaly
-
Matthew BucknorFocused Ultrasound Foundation; InSightec-TxSonicsRecruitingUndifferentiated Pleomorphic SarcomaUnited States
-
Chinese PLA General HospitalRecruitingMovement DisordersChina
-
InSightecTerminatedEssential TremorChina, Japan, Taiwan
-
InSightecActive, not recruitingParkinson DiseaseUnited States, Spain, Taiwan
-
InSightecUnknown